NZ583635A - Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events - Google Patents
Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion eventsInfo
- Publication number
- NZ583635A NZ583635A NZ583635A NZ58363508A NZ583635A NZ 583635 A NZ583635 A NZ 583635A NZ 583635 A NZ583635 A NZ 583635A NZ 58363508 A NZ58363508 A NZ 58363508A NZ 583635 A NZ583635 A NZ 583635A
- Authority
- NZ
- New Zealand
- Prior art keywords
- treatment
- rasburicase
- prophylaxis
- uric acid
- disorders
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 29
- 230000010410 reperfusion Effects 0.000 title claims abstract description 19
- 238000011321 prophylaxis Methods 0.000 title claims abstract description 15
- 230000000302 ischemic effect Effects 0.000 title claims abstract description 8
- 108010092464 Urate Oxidase Proteins 0.000 title description 22
- 229940005267 urate oxidase Drugs 0.000 title description 18
- 108010084837 rasburicase Proteins 0.000 claims abstract description 39
- 229960000424 rasburicase Drugs 0.000 claims abstract description 38
- 239000003814 drug Substances 0.000 claims description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 12
- 206010019280 Heart failures Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 229960005070 ascorbic acid Drugs 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 238000013146 percutaneous coronary intervention Methods 0.000 claims description 6
- 235000010323 ascorbic acid Nutrition 0.000 claims description 5
- 239000011668 ascorbic acid Substances 0.000 claims description 5
- 238000007675 cardiac surgery Methods 0.000 claims description 5
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 4
- 208000010125 myocardial infarction Diseases 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 210000004351 coronary vessel Anatomy 0.000 claims description 3
- 239000002516 radical scavenger Substances 0.000 claims description 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 47
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 47
- 229940116269 uric acid Drugs 0.000 description 47
- 208000028867 ischemia Diseases 0.000 description 29
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 11
- 229960003459 allopurinol Drugs 0.000 description 11
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 229960000458 allantoin Drugs 0.000 description 5
- 229960002163 hydrogen peroxide Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000003642 reactive oxygen metabolite Substances 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004217 heart function Effects 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 241000228197 Aspergillus flavus Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 206010045170 Tumour lysis syndrome Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229960002529 benzbromarone Drugs 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- -1 hydroxyl radicals Chemical class 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000004144 purine metabolism Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 208000010380 tumor lysis syndrome Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000000876 cardiodynamic effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229950002752 oxipurinol Drugs 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 description 2
- 230000001991 pathophysiological effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- LWYOAHYSGAOKDH-UHFFFAOYSA-N 4-hydroxy-3h-purin-2-one Chemical compound C1=NC(O)=NC2(O)N=CN=C21 LWYOAHYSGAOKDH-UHFFFAOYSA-N 0.000 description 1
- LTQYPAVLAYVKTK-YFKPBYRVSA-N 5-Hydroxyisourate Natural products O=C1[C@]2(O)NC(O)=NC2=NC(=O)N1 LTQYPAVLAYVKTK-YFKPBYRVSA-N 0.000 description 1
- LTQYPAVLAYVKTK-UHFFFAOYSA-N 5-hydroxyisouric acid Chemical compound N1C(=O)NC2(O)C1=NC(=O)NC2=O LTQYPAVLAYVKTK-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229950010033 ebselen Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003622 mature neutrocyte Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 208000016839 purine metabolism disease Diseases 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
- C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07291072 | 2007-09-05 | ||
| US1524007P | 2007-12-20 | 2007-12-20 | |
| PCT/EP2008/006858 WO2009030373A1 (en) | 2007-09-05 | 2008-08-20 | Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ583635A true NZ583635A (en) | 2011-06-30 |
Family
ID=38713162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ583635A NZ583635A (en) | 2007-09-05 | 2008-08-20 | Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20100266567A1 (https=) |
| EP (1) | EP2197550A1 (https=) |
| JP (1) | JP2011509920A (https=) |
| KR (1) | KR20100053609A (https=) |
| CN (1) | CN101801460A (https=) |
| AR (1) | AR068360A1 (https=) |
| AU (1) | AU2008295145B2 (https=) |
| BR (1) | BRPI0816406A2 (https=) |
| CA (1) | CA2697929A1 (https=) |
| CL (1) | CL2008002623A1 (https=) |
| CO (1) | CO6260090A2 (https=) |
| IL (1) | IL204259A (https=) |
| MA (1) | MA31624B1 (https=) |
| MX (1) | MX2010001976A (https=) |
| MY (1) | MY183770A (https=) |
| NZ (1) | NZ583635A (https=) |
| PA (1) | PA8794801A1 (https=) |
| PE (1) | PE20090642A1 (https=) |
| TW (1) | TW200927929A (https=) |
| UY (1) | UY31320A1 (https=) |
| WO (1) | WO2009030373A1 (https=) |
| ZA (1) | ZA201000774B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5114972A (en) * | 1990-07-30 | 1992-05-19 | Tsuyoshi Ohnishi | Synthesis and uses of new ascorbic acid derivatives which have anti-oxidant and anti-cancer activities |
| JP2004517804A (ja) * | 2000-06-28 | 2004-06-17 | メルク・アンド・カンパニー・インコーポレーテッド | 心臓血管病の治療法 |
| AU2003275160A1 (en) * | 2002-09-20 | 2004-04-08 | Oregon Health And Science University | Administration of free radical scavengers to prevent or treat ischemia-reperfusion injuries |
| ES2567634T3 (es) * | 2004-02-09 | 2016-04-25 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina |
| WO2005099758A2 (en) * | 2004-04-17 | 2005-10-27 | The Board Of Trustees The Leland Standford Junior University | Injectable bioartificial tissue matrix |
| US20070197512A1 (en) * | 2006-01-27 | 2007-08-23 | Japan Tobacco Inc. | Carboxylic Acid Compounds and Use Thereof |
-
2008
- 2008-08-20 WO PCT/EP2008/006858 patent/WO2009030373A1/en not_active Ceased
- 2008-08-20 KR KR1020107004878A patent/KR20100053609A/ko not_active Ceased
- 2008-08-20 EP EP08785655A patent/EP2197550A1/en not_active Withdrawn
- 2008-08-20 JP JP2010523299A patent/JP2011509920A/ja active Pending
- 2008-08-20 CA CA2697929A patent/CA2697929A1/en not_active Abandoned
- 2008-08-20 CN CN200880105379A patent/CN101801460A/zh active Pending
- 2008-08-20 AU AU2008295145A patent/AU2008295145B2/en not_active Ceased
- 2008-08-20 BR BRPI0816406A patent/BRPI0816406A2/pt not_active IP Right Cessation
- 2008-08-20 NZ NZ583635A patent/NZ583635A/en not_active IP Right Cessation
- 2008-08-20 MX MX2010001976A patent/MX2010001976A/es active IP Right Grant
- 2008-08-20 MY MYPI2010000585A patent/MY183770A/en unknown
- 2008-09-03 TW TW097133674A patent/TW200927929A/zh unknown
- 2008-09-03 UY UY31320A patent/UY31320A1/es not_active Application Discontinuation
- 2008-09-03 PE PE2008001545A patent/PE20090642A1/es not_active Application Discontinuation
- 2008-09-03 AR ARP080103828A patent/AR068360A1/es not_active Application Discontinuation
- 2008-09-03 PA PA20088794801A patent/PA8794801A1/es unknown
- 2008-09-04 CL CL2008002623A patent/CL2008002623A1/es unknown
-
2010
- 2010-02-02 ZA ZA2010/00774A patent/ZA201000774B/en unknown
- 2010-02-22 MA MA32638A patent/MA31624B1/fr unknown
- 2010-02-24 CO CO10021841A patent/CO6260090A2/es not_active Application Discontinuation
- 2010-03-01 US US12/715,061 patent/US20100266567A1/en not_active Abandoned
- 2010-03-02 IL IL204259A patent/IL204259A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200927929A (en) | 2009-07-01 |
| EP2197550A1 (en) | 2010-06-23 |
| MA31624B1 (fr) | 2010-08-02 |
| MY183770A (en) | 2021-03-12 |
| CA2697929A1 (en) | 2009-03-12 |
| WO2009030373A1 (en) | 2009-03-12 |
| MX2010001976A (es) | 2010-03-10 |
| PE20090642A1 (es) | 2009-06-18 |
| UY31320A1 (es) | 2009-04-30 |
| AU2008295145B2 (en) | 2013-12-05 |
| RU2010112867A (ru) | 2011-10-10 |
| ZA201000774B (en) | 2011-04-28 |
| PA8794801A1 (es) | 2009-04-23 |
| CO6260090A2 (es) | 2011-03-22 |
| CN101801460A (zh) | 2010-08-11 |
| KR20100053609A (ko) | 2010-05-20 |
| US20100266567A1 (en) | 2010-10-21 |
| BRPI0816406A2 (pt) | 2017-05-16 |
| CL2008002623A1 (es) | 2009-01-16 |
| JP2011509920A (ja) | 2011-03-31 |
| AR068360A1 (es) | 2009-11-11 |
| AU2008295145A1 (en) | 2009-03-12 |
| IL204259A (en) | 2013-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8852582B2 (en) | Compositions comprising glutathione reductase and oxidized glutathione | |
| JP4842247B2 (ja) | マロニル−ＣｏＡ脱炭酸酵素阻害剤を用いた代謝性疾患の治療法 | |
| Borges et al. | Progress towards the discovery of xanthine oxidase inhibitors | |
| Belardinelli et al. | Oxidative stress, endothelial function and coenzyme Q10 | |
| KR100363069B1 (ko) | 히드록심산유도체를함유하는약제학적조성물 | |
| HU225109B1 (en) | Pharmaceutical compositions comprising antioxidant salen-metal complex and their use | |
| US20090124660A1 (en) | Piperidine Compounds Useful as Malonyl-CoA Decarboxylase Inhibitors | |
| Zou et al. | Protective role of α-lipoic acid in hyperuricemia-induced endothelial dysfunction | |
| JP4727578B2 (ja) | マロニル−ＣｏＡデカルボキシラーゼ阻害剤として有用な複素環式化合物 | |
| US20220105056A1 (en) | N-Acetylcysteine Amide (NACA) and (2R,2R')-3,3' disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) for the Prevention and Treatment of Radiation Dermatitis and Skin Lightening, Skin Whitening and Skin Improvement | |
| US12496332B2 (en) | Composition for preventing, treating, or ameliorating viral infection disease, containing a complex of endoplasmic reticulum (ER) stress inhibitor and reactive oxygen species scavenger as active ingredients | |
| Tripathi et al. | Therapeutic role of L-arginine on free radical scavenging system in ischemic heart diseases | |
| AU2008295145B2 (en) | Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events | |
| RU2482187C2 (ru) | Применение расбуриказы для лечения или профилактики расстройств или косвенных осложнений на сердце, вызванных приступами ишемии или реперфузией | |
| HK1143771A (en) | Use of urate oxidase for the treatment or prophylaxis of disorders or indirect sequelae of the heart caused by ischemic or reperfusion events | |
| CZ74199A3 (cs) | Činidlo pro zvýšení aktivity glutathionreduktasy | |
| JP6364362B2 (ja) | ヒトキマーゼ阻害剤および機能性食品、並びにヒトキマーゼの活性を阻害する方法 | |
| CN119548574B (zh) | 地涌金莲提取物在制备降尿酸产品中的应用 | |
| US20260000645A1 (en) | Use of ebselen or one of the derivatives thereof to treat mitochondrial pathologies or dysfunctions | |
| Fletcher et al. | Cyclosporine A induced changes to plasma and erythrocyte antioxidant defences | |
| Visokinskas et al. | Use of Mildronate in geriatric patients with congestive heart failure | |
| CN104042605A (zh) | Egcg在制备防治心肌能量代谢障碍的食品和药物的应用 | |
| WO2016151090A1 (en) | Methods and pharmaceutical compositions for the treatment of myocardial infarction | |
| NAKAJIMA et al. | Studies on the Control of Plant Diseses by Amino Acid Derivatives (IV) Effect of sodium N-Lauroyl-L-valinate on the metabolism of rice blast fungus | |
| Kolawole et al. | Comparative effects of L-arginine and vitamin C on gentamicin-induced alterations in some biochemical indices of kidney function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |